AVR Anteris Technologies

Anteris Technologies to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Anteris Technologies to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

BRISBANE, Australia and EAGAN, Minn., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Anteris Technologies Ltd (ASX:AVR) (Anteris or the Company), a structural heart company advancing its novel DurAVR™ valve for aortic repair and replacement, today announced that Wayne Paterson, Chief Executive Officer, will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Friday, February 19, 2021 at 10:30AM ET.

About Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™’s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

For more information:

Jason Wong

Blueprint Life Science Group

E:

P: (415) 375-3340 Ext. 4



Twitter: @AnterisTech

Facebook: /AnterisTech



EN
16/02/2021

Underlying

AVRAnteris Technologies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anteris Technologies

 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Reports 2024 Financial Results and Provides Corporate Update

Anteris Reports 2024 Financial Results and Provides Corporate Update EAGAN, Minn. and BRISBANE, Australia, March 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2024, and provided a corporate update. 2024 Full Year Highlights & Recent Developments Achieved a successful U.S. Initial Public Offering (“IPO”...

11h / 53m 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris to Present at Healthcare Investor Conferences - TD Cowen and B...

Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays MINNEAPOLIS and BRISBANE, Australia, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Anteris® Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a structural heart company developing DurAVR® THV, a first-in-class, biomimetic, balloon expandable heart valve, is pleased to advise that Chief Executive Officer, Wayne Paterson will be presenting at both the 45th Annual TD Cowen Healthcare Conference, and the Barclays 27th Annual Global Healthcare Conference. The details of each conference a...

February 28, 2025 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Technologies Announces First Successful Implantation of DurAVR...

BRISBANE, Australia & MINNEAPOLIS--(BUSINESS WIRE)-- Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of biomimetic heart valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve shaped to mimic the performance of a native human aortic valve, announces that the DurAVR™ THV was used for the first time in a valve-in-valve (ViV) procedure as part of Health Canada’s Special Access Program (SAP). This press release features multimedia. View the full release here: Dr Anita Asgar (centre) Co-Di...

July 31, 2023 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Technologies Announces $20M Private Placement with Perceptive ...

Anteris Technologies Announces $20M Private Placement with Perceptive Advisors BRISBANE, Australia and EAGAN, Minn., March 02, 2022 (GLOBE NEWSWIRE) -- Anteris Technologies Ltd (Anteris or the Company) Limited (ASX: AVR) announces the Company has entered a binding agreement to place 1,840,000 new Ordinary Shares (New Shares) raising USD 20 million ($A 28 million) to Perceptive Life Sciences Master Fund, Ltd and managed by Perceptive Advisors (Perceptive) at $A15 a share, representing a 20% discount to the closing price on 28 February 2022. This transaction makes Perceptive Advisors Anter...

March 2, 2022 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Technologies to Present at the BTIG Virtual MedTech, Digital H...

Anteris Technologies to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference BRISBANE, Australia and EAGAN, Minn., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Anteris Technologies Ltd (ASX:AVR) (Anteris or the Company), a structural heart company advancing its novel DurAVR™ valve for aortic repair and replacement, today announced that Wayne Paterson, Chief Executive Officer, will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Friday, February 19, 2021 at 10:30AM ET. About Anteris Technologies Ltd (AS...

February 16, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch